Prevalence of resistance to three fluoroquinolones: Assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility

被引:6
作者
Fuchs, PC
Barry, AL
Brown, SD
Allen, S
Bauman, M
Bruckner, D
Hindler, J
Doern, G
Ferraro, MJ
Hardy, D
Jenkins, S
McLaughlin, J
Murray, P
Sewell, D
机构
关键词
D O I
10.1128/AAC.40.7.1633
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
More than 3,000 consecutive clinical bacterial isolates from 10 U.S. medical centers were subjected to standard broth microdilution and disk diffusion tests to determine their susceptibilities to levofloxacin, ofloxacin, D-ofloxacin, and ciprofloxacin. Levofloxacin was confirmed to be twice as active as ofloxacin and to have activity comparable to that of ciprofloxacin, with minor variations in activity against some species. The prevalence of resistant isolates was 7.1% to levofloxacin, 9.3% to ciprofloxacin, and 11.2% to ofloxacin. The susceptibilities of some species to the quinolones were less than those reported in previous studies. Pseudomonas aeruginosa isolates had the greatest variability in their susceptibilities to the three drugs between the participating centers. Two proposed zone size breakpoints for levofloxacin disk tests yielded similar low error rates, Ofloxacin and ciprofloxacin susceptibility test results correlated reasonably well with those of levofloxacin and could be used as surrogate indicators of levofloxacin susceptibility, but that resulted in some serious errors, and thus, direct testing of levofloxacin susceptibility is preferable. Replicate testing of standard quality control strains confirmed the established and proposed quality control parameters for all three quinolones tested.
引用
收藏
页码:1633 / 1639
页数:7
相关论文
共 29 条
[1]   MINIMUM INHIBITORY CONCENTRATION QUALITY-CONTROL GUIDELINES FOR BIAPENEM, DU-6859A, FK-037, LEVOFLOXACIN, GREPAFLOXACIN, AND CEFTIZOXIME WHEN USING VARIOUS NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS SUSCEPTIBILITY TEST METHODS [J].
BALE, MJ ;
JONES, RN ;
ERWIN, ME ;
MURRAY, PR ;
WASHINGTON, JA ;
GERLACH, EH ;
THORNSBERRY, C ;
HINDLER, J ;
DOERN, GV .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1994, 19 (01) :65-68
[2]   INTERPRETIVE CRITERIA AND QUALITY-CONTROL FOR ANTIMICROBIAL SUSCEPTIBILITY TESTS OF LEVOFLOXACIN [J].
BARRY, A ;
FUCHS, P ;
TENOVER, F ;
ALLEN, S ;
HARDY, D ;
JORGENSEN, J ;
MCLAUGHLIN, J ;
RELLER, L .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1994, 13 (10) :822-826
[3]   A COMPARISON OF ANTIMICROBIAL ACTIVITY OF OFLOXACIN, L-OFLOXACIN, AND OTHER ORAL-AGENTS FOR RESPIRATORY PATHOGENS [J].
CHERUBIN, CE ;
ENG, RHK ;
SMITH, SM ;
TAN, EN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1992, 15 (02) :141-144
[4]   SUSCEPTIBILITY TO LEVOFLOXACIN PREDICTED FROM IN-VITRO SUSCEPTIBILITY TESTING RESULTS OBTAINED WITH CIPROFLOXACIN AND WITH OFLOXACIN [J].
CORMICAN, MG ;
JONES, RN .
JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (01) :215-216
[5]  
DAUM TE, 1980, ANTIMICROB AGENTS CH, V34, P18562
[6]   SUSCEPTIBILITIES OF BACTERIAL ISOLATES FROM PATIENTS WITH CANCER TO LEVOFLOXACIN AND OTHER QUINOLONES [J].
DHOLAKIA, N ;
ROLSTON, KVI ;
HO, IH ;
LEBLANC, B ;
BODEY, GP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :848-852
[7]   INVITRO ACTIVITY OF L-OFLOXACIN AGAINST NORFLOXACIN-RESISTANT COAGULASE-NEGATIVE STAPHYLOCOCCI [J].
FOLENO, B ;
FU, KP .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1992, 15 (06) :557-559
[8]  
FOLENO BD, 1983, MICROBIOLOGY, V39, P120
[9]   INVITRO AND INVIVO ANTIBACTERIAL ACTIVITIES OF LEVOFLOXACIN (L-OFLOXACIN), AN OPTICALLY-ACTIVE OFLOXACIN [J].
FU, KP ;
LAFREDO, SC ;
FOLENO, B ;
ISAACSON, DM ;
BARRETT, JF ;
TOBIA, AJ ;
ROSENTHALE, ME .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (04) :860-866
[10]   OFLOXACIN SUSCEPTIBILITY TESTING QUALITY-CONTROL PARAMETERS FOR MICRODILUTION AND DISK DIFFUSION, AND CONFIRMATION OF DISK DIFFUSION INTERPRETIVE CRITERIA [J].
FUCHS, PC ;
JONES, RN ;
BARRY, AL ;
GAVAN, TL .
JOURNAL OF CLINICAL MICROBIOLOGY, 1989, 27 (01) :49-52